These results showed that HLX might play different roles, as a cancer-suppressor gene or a cancer-promoting gene, depending on the stage of CRC, and clinicians might potentially use HLX expression as a biomarker to predict patient outcomes and tailor treatment plans accordingly. The gene discussed is HLX; the disease is cancer.